Stathmin表达与局部晚期口腔鳞癌患者TPF诱导化疗远期疗效的相关性分析

doi:10.19438/j.cjoms.2021.03.006

中国口腔颌面外科杂志 ›› 2021, Vol. 19 ›› Issue (3): 217-221.doi: 10.19438/j.cjoms.2021.03.006

Stathmin表达与局部晚期口腔鳞癌患者TPF诱导化疗远期疗效的相关性分析

谈亦然¹, 赵铜超¹, 王丽珍², 李江², 琚梧桐^1,*, 朱东旺¹, 张志愿¹, 钟来平^1,*

1.上海交通大学医学院附属第九人民医院口腔颌面-头颈肿瘤科,
2.口腔病理科,上海交通大学口腔医学院,国家口腔医学中心,国家口腔疾病临床医学研究中心,上海市口腔医学重点实验室,上海 200011

收稿日期:2020-12-07 修回日期:2021-03-11 发布日期:2021-07-16
通讯作者: 琚梧桐,E-mail：juwutong@163.com;钟来平,E-mail：zhonglaiping@163.com。^*共同通信作者
作者简介:谈亦然（1988-）,男,硕士,医师,E-mail：gordon-tan@foxmail.com
基金资助:
国家自然科学基金（81972525、81672660）; 上海市卫生健康委员会学科带头人计划（2018BR41）; 上海交通大学医学院附属第九人民医院临床研究型MDT项目（201916）

Stathmin expression correlated with the long-term survival benefit from TPF induction chemotherapy in patients with locally advanced oral squamous cell carcinoma

TAN Yi-ran¹, ZHAO Tong-chao¹, WANG Li-zhen², LI Jiang², JU Wu-tong¹, ZHU Dong-wang¹, ZHANG Zhi-yuan¹, ZHONG Lai-ping¹

1. Department of Oromaxillofacial Head and Neck Oncology,
2. Department of Oral Pathology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine; College of Stomatology, Shanghai Jiao Tong University; National Center for Stomatology; National Clinical Research Center for Oral Diseases; Shanghai Key Laboratory of Stomatology. Shanghai 200011, China

Received:2020-12-07 Revised:2021-03-11 Published:2021-07-16

摘要/Abstract

摘要： 目的验证微管解聚蛋白（Stathmin）能否预测口腔鳞癌（oral squamous cell carcinoma,OSCC）患者从多西紫杉醇、顺铂、5氟尿嘧啶（TPF）诱导化疗中远期获益。方法收集2008年3月—2010年12月入组TPF诱导化疗临床试验的256例OSCC患者的远期随访结果。收集患者肿瘤活检标本,进行Stathmin免疫组织化学染色并评分。根据Stathmin表达评分进行亚组预后分析。采用SPSS 13.0软件包将Stathmin和其他基线特征进行单因素、多因素和Cox回归模型预后分析。结果 Stathmin的表达可预测OSCC患者对TPF诱导化疗的反应,Stathmin低表达的OSCC患者从TPF诱导化疗中获益,而高Stathmin表达的OSCC患者不能获益于TPF诱导化疗。Stathmin的表达是独立的预测因子。结论 Stathmin是独立的预测OSCC诱导化疗疗效的生物标志物,基于Stathmin筛选指导OSCC患者接受TPF诱导化疗的后续临床研究具有重要意义。

关键词: 口腔鳞癌, 微管解聚蛋白, 诱导化疗, 预后

Abstract: PURPOSE: This study analyzed the role of Stathmin as a predictive biomarker on the long-term benefit of TPF induction chemotherapy based on a 11-year follow-up results. METHODS: Long-term follow-up results of 256 oral squamous cell carcinoma (OSCC) patients enrolled in the TPF induction chemotherapy trial were collected. Tumor biopsy specimens were collected for Stathmin immunohistochemical staining and scoring. Subgroup prognosis was analyzed according to the Stathmin expression. Stathmin and other baseline characteristics were analyzed by univariate, multivariate, and Cox regression model with SPSS 13.0 software package. RESULTS: Stathmin expression predicted the response of TPF induction chemotherapy in OSCC patients. OSCC patients with lower Stathmin expression benefited from TPF induction chemotherapy, while OSCC patients with higher Stathmin expression did not benefit from TPF induction chemotherapy. Stathmin expression was an independent predictor of long-term prognosis. CONCLUSIONS: Stathmin is an independent biomarker for predicting the efficacy of TPF induction chemotherapy in OSCC. Subsequent clinical studies based on Stathmin screening will be meaningful for choice of TPF induction chemotherapy in OSCC.

Key words: Oral squamous cell carcinoma, Stathmin, Induction chemotherapy, Prognosis

中图分类号:

R739.8

谈亦然, 赵铜超, 王丽珍, 李江, 琚梧桐, 朱东旺, 张志愿, 钟来平. Stathmin表达与局部晚期口腔鳞癌患者TPF诱导化疗远期疗效的相关性分析[J]. 中国口腔颌面外科杂志, 2021, 19(3): 217-221.

TAN Yi-ran, ZHAO Tong-chao, WANG Li-zhen, LI Jiang, JU Wu-tong, ZHU Dong-wang, ZHANG Zhi-yuan, ZHONG Lai-ping. Stathmin expression correlated with the long-term survival benefit from TPF induction chemotherapy in patients with locally advanced oral squamous cell carcinoma[J]. China J Oral Maxillofac Surg, 2021, 19(3): 217-221.

参考文献

[1] Zhong LP, Zhang ZY.Reply to K. Devisetty et al[J]. J Clin Oncol, 2013, 31(23): 2972-2973.
[2] Ma HL, Jin SF, Ju WT, et al.Stathmin is overexpressed and regulated by mutant p53 in oral squamous cell carcinoma[J]. J Exp Clin Cancer Res, 2017, 36(1): 109-123.
[3] Ju WT, Ma HL, Zhao TC, et al.Stathmin guides personalized therapy in oral squamous cell carcinoma[J]. Cancer Sci, 2020, 111(4): 1303-1313.
[4] Tanaka C, Uzawa K, Shibahara T, et al.Expression of an inhibitor of apoptosis, survivin, in oral carcinogenesis[J]. J Dent Res, 2003, 82(8): 607-611.
[5] Khoo E, O'Neill S, Brown E, et al. Systematic review of systemic adjuvant, neoadjuvant and perioperative chemotherapy for resectable colorectal-liver metastases[J]. HPB (Oxford), 2016,18(6): 485-493.
[6] Riba LA, Russell T, Alapati A, et al.Characterizing response to neoadjuvant chemotherapy in invasive lobular breast carcinoma[J]. J Surg Res, 2019, 233: 436-443.
[7] Bossi P, Lo VS, Guzzo M, et al.Preoperative chemotherapy in advanced resectable OCSCC: long-term results of a randomized phase III trial[J]. Ann Oncol, 2014, 25(2): 462-466.
[8] Cohen EE, Karrison TG, Kocherginsky M, et al.PhaseⅢrandomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer[J]. J Clin Oncol, 2014, 32(25): 2735-2743.
[9] Maghami E, Koyfman SA, Weiss J.Personalizing postoperative treatment of head and neck cancers[J]. Am Soc Clin Oncol Educ Book, 2018, 38: 515-522.
[10] Kim R, Hahn S, Shin J, et al.The effect of induction chemotherapy using docetaxel, cisplatin, and fluorouracil on survival in locally advanced head and neck squamous cell carcinoma: a meta-analysis[J]. Cancer Res Treat, 2016, 48(3): 907-916.

[1]	陈华, 李婧, 罗梅. 红景天甙通过NRF2/KEAP1通路对口腔鳞癌细胞生长的影响[J]. 中国口腔颌面外科杂志, 2024, 22(5): 424-429.
[2]	古丽斯旦·麦吾拉江, 李晨曦, 龚忠诚, 热依拉·居热提, 姬晓炜. 口腔种植体周围菌群对种植体周围炎影响的meta分析[J]. 中国口腔颌面外科杂志, 2024, 22(5): 478-486.
[3]	黄灿, 罗涛, 孙宇. 改良衰弱评估对行口腔鳞癌皮瓣重建术老年患者术后并发症的预测价值[J]. 中国口腔颌面外科杂志, 2024, 22(4): 373-377.
[4]	张银银, 朱岩岩, 丁嘉慧, 孙玉华. 144例口腔颌面部间隙感染并发症及入ICU监护的危险因素分析[J]. 中国口腔颌面外科杂志, 2024, 22(2): 148-152.
[5]	张强, 李庆, 张佳. 颌骨骨肉瘤25例影像与临床预后分析[J]. 中国口腔颌面外科杂志, 2024, 22(2): 186-191.
[6]	李华盛, 周迪, 韩楠男, 严明, 阮敏. 石蒜碱通过降解SCAP蛋白抑制口腔鳞癌细胞增殖与侵袭的实验研究[J]. 中国口腔颌面外科杂志, 2024, 22(1): 29-35.
[7]	刘恒, 李永頔, 尹鑫海, 段晓峰. 铁蛋白重链1在头颈鳞癌中的表达及对口腔鳞癌增殖、迁移、侵袭的影响[J]. 中国口腔颌面外科杂志, 2023, 21(6): 529-537.
[8]	赵铜超, 梁思源, 周知航, 朱方兴, 琚梧桐, 谈亦然, 刘莹, 钟来平. BMI与局部晚期口腔鳞癌患者预后及诱导化疗效果的相关性研究[J]. 中国口腔颌面外科杂志, 2023, 21(6): 559-565.
[9]	朱方兴, 周知航, 琚梧桐, 谈亦然, 刘莹, 钟来平, 赵铜超. 基于基线期dNLR水平对局部晚期口腔鳞癌患者生存的预后预测—10年临床回顾[J]. 中国口腔颌面外科杂志, 2023, 21(6): 566-571.
[10]	靳能皓, 田瑜, 朱亮, 乔波, 李粮博, 张海钟, 张蕾. PD-L1及肿瘤免疫微环境对预测口腔鳞癌新辅助治疗效果的意义[J]. 中国口腔颌面外科杂志, 2023, 21(6): 572-578.
[11]	程煜天, 徐乐, 马利, 吴海威, 陈占伟, 邹虎威, 张天奇, 刘桂军, 刘振兴, 尹长伟, 李文刚, 张世周, 黄圣运, 张东升. 头颈部腺样囊性癌预后分析：单中心经验[J]. 中国口腔颌面外科杂志, 2023, 21(5): 467-471.
[12]	吴朱昊, 张兴伟, 孙亚威, 李子慧, 陈欣, 蒲玉梅, 胡勤刚, 董迎春, 孙国文. ICG荧光导航技术在晚期口腔鳞癌救治性手术中的应用[J]. 中国口腔颌面外科杂志, 2023, 21(3): 248-252.
[13]	苏姿尚, 崔文丽, 张梦云, 姚志涛. 口腔鳞状细胞癌患者颈部淋巴结特征与预后的关系[J]. 中国口腔颌面外科杂志, 2023, 21(1): 41-48.
[14]	刘恒, 段晓峰. 铁自噬及相关基因NCOA4、FTH1在口腔鳞癌中的研究进展[J]. 中国口腔颌面外科杂志, 2023, 21(1): 87-91.
[15]	杨慧丽, 王宇帆, 王锋, 沈月洪, 杨宏宇. NLRP1在头颈部鳞癌中的表达及预后意义[J]. 中国口腔颌面外科杂志, 2022, 20(5): 429-436.

Stathmin表达与局部晚期口腔鳞癌患者TPF诱导化疗远期疗效的相关性分析

Stathmin expression correlated with the long-term survival benefit from TPF induction chemotherapy in patients with locally advanced oral squamous cell carcinoma

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价